BTIG Research Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock Price

OrthoPediatrics (NASDAQ:KIDS) had its price objective hoisted by equities research analysts at BTIG Research from $24.00 to $29.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 9.43% from the company’s current price.

A number of other research analysts have also recently commented on KIDS. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research note on Wednesday, August 5th. Needham & Company LLC raised their target price on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.44.

OrthoPediatrics Price Performance

KIDS opened at $26.50 on Thursday. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics has a 52-week low of $14.42 and a 52-week high of $26.71. The company has a 50 day moving average of $20.53 and a two-hundred day moving average of $18.29. The company has a market cap of $691.91 million, a P/E ratio of -15.77 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. On average, analysts expect that OrthoPediatrics will post -1.14 earnings per share for the current year.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares during the last quarter. Millennium Management LLC boosted its stake in OrthoPediatrics by 55.3% during the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after acquiring an additional 233,873 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares during the last quarter. Jane Street Group LLC acquired a new position in OrthoPediatrics during the 1st quarter worth $389,000. Finally, American Century Companies Inc. grew its holdings in OrthoPediatrics by 12.5% during the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock worth $741,000 after acquiring an additional 3,828 shares in the last quarter. 69.05% of the stock is owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.